SYI 2074

Drug Profile

SYI 2074

Alternative Names: ALT-2074; BXT 51072; SYN-2074

Latest Information Update: 08 Apr 2009

Price : $50

At a glance

  • Originator OXIS Therapeutics
  • Developer OXIS Therapeutics; Synvista Therapeutics
  • Class Anti-inflammatories; Anti-ischaemics; Organoselenium compounds; Small molecules
  • Mechanism of Action Antioxidants; Cell adhesion molecule inhibitors; Glutathione peroxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute coronary syndromes; Asthma; Chronic obstructive pulmonary disease; Hepatitis; Plaque psoriasis; Respiratory distress syndrome; Septic shock; Ulcerative colitis

Most Recent Events

  • 28 Jan 2009 Discontinued - Phase-II for Plaque psoriasis in Israel (Topical)
  • 15 Dec 2008 Phase-II clinical trials in Plaque psoriasis in Israel (Topical)
  • 29 Sep 2008 Israeli Ministry of Health grants approval for a phase I/II trial of SYI 2074 in Plaque psoriasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top